Abstract Text: The analysis of kappa and lambda surface light chains is a critical test for assessing the presence of a single, abnormal clone of cells (known as clonality) in blood cancer research. When designing an antibody panel for flow cytometry targeting kappa and lambda light chains, it is important to consider the specificity of the antibodies and the level of antigen expression in the populations of interest. Polyclonal antibodies have traditionally been used in designing antibody panels for the detection of light chains in B cell lymphoproliferative disorders research. These polyclonal reagents have become the gold standard in kappa/lambda detection to characterize B cell disorders, however, several monoclonal antibodies have also been developed in recent years. This could be an advantage for researchers in the field as monoclonal kappa and lambda antibodies offer higher manufacturing reproducibility while preserving high specificity and sensitivity. In this study, we compared the performance of BioLegend monoclonal kappa and lambda light chains conjugated antibodies with gold standard polyclonal kappa and lambda antibodies. Our findings indicate that BioLegend monoclonal antibodies exhibited significantly higher median fluorescence intensities and stain indices than the polyclonal antibodies. These results demonstrate a consistent and comparable performance of our monoclonal antibodies. Additionally, researchers could benefit from our wide conjugate offering and our capabilities to conjugate antibodies to a variety of suitable fluorophores for expanded flow cytometry panel selection to better understand the biology of blood cancers.
